| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FARSLB |
| Uniprot No | Q9NSD9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-589aa |
| 氨基酸序列 | MPTVSVKRDLLFQALGRTYTDEEFDELCFEFGLELDEITSEKEIISKEQGNVKAAGASDVVLYKIDVPANRYDLLCLEGLVRGLQVFKERIKAPVYKRVMPDGKIQKLIITEETAKIRPFAVAAVLRNIKFTKDRYDSFIELQEKLHQNICRKRALVAIGTHDLDTLSGPFTYTAKRPSDIKFKPLNKTKEYTACELMNIYKTDNHLKHYLHIIENKPLYPVIYDSNGVVLSMPPIINGDHSRITVNTRNIFIECTGTDFTKAKIVLDIIVTMFSEYCENQFTVEAAEVVFPNGKSHTFPELAYRKEMVRADLINKKVGIRETPENLAKLLTRMYLKSEVIGDGNQIEIEIPPTRADIIHACDIVEDAAIAYGYNNIQMTLPKTYTIANQFPLNKLTELLRHDMAAAGFTEALTFALCSQEDIADKLGVDISATKAVHISNPKTAEFQVARTTLLPGLLKTIAANRKMPLPLKLFEISDIVIKDSNTDVGAKNYRHLCAVYYNKNPGFEIIHGLLDRIMQLLDVPPGEDKGGYVIKASEGPAFFPGRCAEIFARGQSVGKLGVLHPDVITKFELTMPCSSLEINIGPFL |
| 分子量 | 90.53 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FARSLB蛋白的模拟参考文献示例。由于该蛋白研究较为专业，实际文献可能需要通过学术数据库进一步检索确认：
---
1. **文献名称**：*Expression, Purification, and Functional Analysis of Recombinant Human FARSLB Protein*
**作者**：Smith A, et al.
**摘要**：本研究成功构建了重组人源FARSLB蛋白的原核表达系统，通过大肠杆菌表达并优化纯化条件。实验表明，纯化的FARSLB具有氨基酰化酶活性，并能与α亚基形成复合物，提示其在tRNA苯丙氨酸负载中的关键作用。
2. **文献名称**：*Structural Insights into the Mitochondrial Localization of FARSLB*
**作者**：Zhang L, et al.
**摘要**：通过冷冻电镜技术解析了人源FARSLB蛋白的晶体结构，揭示了其N端线粒体靶向信号序列的构象特征。研究为FARSLB在线粒体蛋白质合成中的功能机制提供了结构基础。
3. **文献名称**：*FARSLB Deficiency and Its Association with Neurodevelopmental Disorders*
**作者**：Johnson R, et al.
**摘要**：研究发现FARSLB基因突变导致患者线粒体tRNA苯丙氨酸氨基酰化功能受损，引发神经元发育异常。体外实验通过重组FARSLB蛋白回补验证了其功能恢复潜力。
---
**说明**：
- 上述文献为模拟示例，实际研究中关于FARSLB的报道可能有限，建议通过PubMed、Web of Science等平台以**“FARSB”(基因别名)**或**“phenylalanyl-tRNA synthetase beta subunit”**为关键词检索。
- 部分研究可能侧重其与α亚基(FARSA)的复合体功能，可扩展搜索范围至“氨酰-tRNA合成酶复合物”相关文献。
- 如需具体文献指引，建议结合研究方向补充关键词(如疾病、结构、表达系统等)。
FARSLB (Phenylalanyl-tRNA Synthetase Beta Subunit) is a critical component of the cytosolic phenylalanyl-tRNA synthetase (PheRS), an enzyme essential for protein biosynthesis. PheRS belongs to the aminoacyl-tRNA synthetase (ARS) family, which catalyzes the attachment of phenylalanine to its cognate tRNA, ensuring fidelity during mRNA translation. In humans, functional PheRS is a heterotetramer composed of two alpha (FARSA) and two beta (FARSLB) subunits. FARSLB stabilizes the complex and enhances catalytic efficiency, while FARSA carries the active site for aminoacylation.
Recombinant human FARSLB is produced via genetic engineering in expression systems like *E. coli* or mammalian cells, enabling studies of its structural and functional roles. Dysregulation of FARSLB has been linked to neuropathies and cancers, as ARS mutations often impair translational accuracy or trigger non-canonical signaling pathways. For example, biallelic FARSLB variants are associated with neurodevelopmental disorders, including Charcot-Marie-Tooth disease.
Research on recombinant FARSLB aids in elucidating its molecular interactions, structure-guided drug design, and mechanisms underlying ARS-related pathologies. It also serves as a tool for screening therapeutic inhibitors targeting tRNA synthetases in proliferative diseases.
×
